Though federal agencies are hungry for new technology solutions, a report from the Government Accountability Office says they may be missing out on a key avenue of innovation.
Having analyzed the trends and the shifting winds in the payer marketplace, it’s time to gaze into the crystal ball and see what the future has in store.
“If you can look into the seeds of time, and say which grain will grow and which will not, speak then unto me,” Banquo beseeches the witches in Shakespeare’s “Macbeth,” seeking insight into the future for himself and his closest friend Macbeth.
Peloton tops the list of NYC fund raisers in 2018, followed by WeWork and Letgo.
Though the healthcare field is notoriously slow to adopt new technologies, IT innovation is making its way to the sector. Looking ahead, what does the future of technology in the medical world look like? One hospital executive weighed in.
New funding will support Phase 1 studies for Spiral Therapeutics’ lead drug candidate targeting inner ear disorders and hearing loss.
Baltimore startup emocha is working with a local healthcare organization on a new pilot that brings its mobile video technology to Type 2 diabetes patients in the city.
The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.
The Maryland Department of Commerce is seeking BioHealth companies with an interest in participating in a trade mission to the United Kingdom hosted by British Midlands Engine.
The University of Maryland, Baltimore has granted Educational & Scientific, LLC an exclusive license with the potential to treat prostate cancer, UM Ventures announced Monday. The agreement allows Educational & Scientific to develop Galeterone, a molecule that could inhibit prostate cancer growth in patients with castration-resistant prostate cancer. The molecule has had successful Phase 1 and Phase …